Physician profile
Ralph V Fiore, II
NPI 1770524043
$47,641.25
in general payments reported to CMS, 2019-2025
24 companies · $9,512 in 2025
The $9,512 reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $2,682 · 2021: $207 · 2022: $1,068 · 2023: $20K · 2024: $14K · 2025: $9,512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Consulting Fee: $15K · Food and Beverage: $6,773 · Travel and Lodging: $5,712 · Education: $45.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,870.00 |
| Consulting Fee | $14,711.00 |
| Food and Beverage | $6,772.98 |
| Travel and Lodging | $5,712.42 |
| Education | $45.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $21,013.91 | 2019-2025 | |
| Genzyme Corporation | $7,701.46 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $7,513.33 | 2023-2025 | Zoryve |
| Amgen INC. | $4,385.22 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $1,312.40 | 2019-2025 | |
| Celgene Corporation | $1,301.54 | 2020 | |
| Incyte Corporation | $636.75 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $629.94 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $508.39 | 2023-2024 | Sotyktu |
| Ucb, INC. | $504.35 | 2022-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $485.21 | 2022-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $411.56 | 2022-2024 | Vtama |
| Lilly USA, LLC | $295.88 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $291.84 | 2022-2025 | Ilumya, Winlevi |
| Leo Pharma INC. | $144.57 | 2022-2025 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $143.89 | 2024-2025 | Nemluvio |
| Botanix Sb INC | $90.04 | 2025 | Sofdra |
| Biofrontera INC. | $64.91 | 2022-2025 | Ameluz, Rhodoled Xl, Xepi |
| Janssen Biotech, INC. | $64.14 | 2022-2024 | Simponi Aria, Simponi, Stelara |
| Organon LLC | $48.17 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.77 | 2025 | Spevigo |
| Sandoz INC. | $23.07 | 2024 | Hyrimoz |
| Journey Medical Corporation | $20.18 | 2024 | |
| Sensus Healthcare, INC. | $16.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Fiore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.